

McLAREN PORT HURON
2023 ANTIBIOPGRAM
DRUG THERAPY POCKET GUIDE



**ANTIMICROBIAL SUSCEPTIBILITIES FROM
JANUARY 1, 2022 – DECEMBER 31, 2022**

*For questions, please contact the
McLaren Port Huron Pharmacy at (810) 985-2644*

McLaren
PORT HURON

DOING WHAT'S BEST.®

1221 Pine Grove Ave. | Port Huron, Michigan 48060
mclaren.org/porthuron

Jan 1, 2022 - Dec 31, 2022																											
Numbers Represent % Susceptibility Inpatient + Outpatient (1st Isolate of a species per patient)																											
GRAM NEGATIVE BACTERIA																											
GRAM POSITIVE BACTERIA																											
Number of isolates	38	48	174	1855	138	460	80	290	411	93	493	99	86	509	701 * = 64	202 * = 112	Enterococcus faecalis	Enterococcus faecium	Vancomycin Resistant Enterococcus species	MRSA	Staphylococcus aureus (MSSA)	Staphylococcus epidermidis	Staphylococcus hominis	Staphylococcus lugdunesis	Streptococcus agalactiae	Streptococcus pneumoniae	
Amikacin	97	100	100	99	100	99	100	98	95	100					100	49	48	92						95			
Ampicillin-Sulbactam	89	60	83	65	72	83	3	88							99	16	27								100		
Aztreonam	27	27	58				73								62*	33									68		
Cefazolin	2	2	85	47	87	91	91	90	92	92	79	74			100*	49	48	92									
Cefepime	84	100	90	97	97	92	98	95	88	98					100*	53*	48								95		
Cefotaxime	86	66	81	91	97	91	86	95	92	66					100*	55*	48								95		
Ceftazidime	52	62	71	90	93	91	84	95	73						100*	49	48	92							90		
Cefuroxime	86	87	94	82	98	93	90	64	84	98	75	9			26	85	67	78	96								
Ciprofloxacin															66	73	61	67	74	45	90						
Clindamycin															100	100	100	100	100	100	100	100	100	100	100	100	
Daptomycin															100	100	100	100	100	100	100	100	100	100	100	100	
Ertapenem	100	89	99	100	99	98	100								100												
Erythromycin															27		16	56	30*	32	74	38	63				
Gentamicin	94	95	89	98	95	90	94	89	100						98	96	86	90	100								
Gent Synergy	86	91	97	83	98	96	94	71	83	100	78	12			27	88	67	78	96	97	100						
Levofloxacin															98	98	97	100	100	100	100	100	100	100	100	100	
Linetzolid	94	100	100	100	100	100	100	100	93	100					98	98	97	100	100	100	100	100	100	100	100		
Meropenem															99	58	62										
Nitrofurantoin *for uncomplicated UTI	92	24	97	90	43										100	49	48	92									
Oxacillin															93	18	26										
Penicillin															91	89	98	94	95	100	91	82					
Piperacillin-Tazobactam															51	10	24	99	99	100	100	100					
Rifampin		84	87	86	86	85	85	33	11	30	36	11	89	93	82	82	82	88	81								
Tetracyclines																											
Tobramycin																											
Trimethoprim - Sulfaemethoxazole	81	87	92	77	94	89	87	68	100						94	39											
Vancomycin															100	100	100	100	100	100	100	100	100	100	100	100	

Blue highlighting indicates organisms that crossed above 80% susceptible compared to 2021; Red highlighting indicates organisms that crossed below 80% susceptible compared to 2021 data

Antibiotic dosing based on normal renal function

(pharmacist will really adjust as needed according to renal dosing policy)

Antimicrobials	Usual Dose per indication							
Acyclovir IV	HSV Suppression = 2.5 mg/kg q8h		HSV Treatment = 5 mg/kg q8h			Herpes Zoster or Encephalitis = 10 mg/kg q8h		
Acyclovir PO	HSV Suppression = 400 mg q12h		HSV Treatment = 400 mg three times daily			Herpes Zoster or Encephalitis = 800 mg five times daily		
Amoxicillin PO	Pneumonia = 1 gm q8h			Systemic Infection = 500 mg q8h				
Amoxicillin/clavulanate PO	875 mg q12h							
Ampicillin IV	Systemic Infection = 2 gm q6h			Bloodstream/Endocarditis/CNS Infection = 2 gm q4h				
Ampicillin/sulbactam IV	Systemic Infection = 3 gm q6h			Acinetobacter Infection = Contact ID physician/ pharmacy for dosing assistance. Sulbactam is the active component. Higher than typical doses may be indicated for this pathogen.				
Aztreonam IV*	Systemic Infection = 2 gm q8h			CNS Infection = 2 gm q6h				
Cefazolin IV	Systemic Infection = 2 gm q8h			Cystitis (lower urinary tract infection) = 1 gm q8h				
Cefdinir PO	300 mg q12h							
Cefepime IV*	Systemic Infection = 2 gm q8h			Cystitis (lower urinary tract infection) = 1 gm q8h				
Cefoxitin IV	2 gm q6h							
Ceftazidime IV*	2 gm q8h							
Ceftazidime/avibactam IV	2.5 gm q8h							
Ceftriaxone IV	Systemic Infection = 2 gm daily			Cystitis (lower urinary tract infection) = 1 gm daily				
Ceftizoxane/tazobactam IV	Pulmonary Infections/Sepsis = 3 gm q8h			Non-pulmonary Infections = 1.5 gm q8h				
Cephalexin PO	Systemic Infection = 500 mg q6h			Cystitis (lower urinary tract infection) = 500 mg q12h				
Ciprofloxacin IV	Systemic Infection = 400 mg q8h			Cystitis (lower urinary tract infection) = 400 mg q12h				
Ciprofloxacin PO	Systemic Infection = 750 mg q12h			Cystitis (lower urinary tract infection) = 500 mg q12h				
Daptomycin IV	Skin & Soft Tissue/ Urinary Tract Infection = 4 mg/kg q24h	Bacteremia/ Endocarditis = 6 mg/kg q24h		VRE Bacteremia/Endocarditis = 10 mg/kg q24h				
Ertapenem IV	1 gm q24h							
Fluconazole IV/PO	Oropharyngeal Thrush/ Urinary Tract Infection = 200 mg q24h	Invasive Candida Infection = 800 mg x1, followed by 400 mg q24h			Candida glabrata Infection = 800 mg q24h			
Ganciclovir IV	CMV Induction = 5 mg/kg q12h			CMV Maintenance = 5 mg/kg q24h				
Levofloxacin IV/PO	Systemic Infection = 750 mg q24h			Cystitis (lower urinary tract infection) = 500 mg q24h				
Meropenem IV*	Systemic Infection = 500 mg q6h			CNS, CF, Documented Pseudomonas or Acinetobacter non-urinary infection = 2 g q8h				
Oseltamivir PO	Treatment = 75 mg q12h			Prophylaxis = 75 mg q24h				
Penicillin G IV	Standard/ Maximum Dose/ Endocarditis/ Necrotizing Fasciitis/ Toxic Shock Syndrome = 4 million units q4h			Reduced Dose (Highly Penicillin-Sensitive Organisms; MIC ≤ 0.12 mcg/mL)/ Endocarditis = 2 million units q4h				
Piperacillin/tazobactam IV*	3.375 gm q8h							
Sulfamethoxazole-trimethoprim IV (weight-based dosing is based on the trimethoprim component)	Systemic Infection (Non-Urinary) = 5 mg/kg q12h			PCP Pneumonia/ Nocardia/ Meningitis = 5 mg/kg q8h				
Sulfamethoxazole-trimethoprim PO	Systemic Infection = 1-2 DS tablets q12h			Cystitis (lower urinary tract infection) = 1 DS tablet q12h				
Valacyclovir PO	1 st Episode HSV = 1 gm q12h	Recurrent HSV = 500 mg q12h	Recurrent HSV – Immunocompromised = 1 gm q12h	HSV Suppression = 500 mg to 1000 mg 24h	HSV Suppression – Immunocompromised = 500 mg q12h	Shingles/ VZV = 1 gm q8h		

*Extended Interval Dosing utilized, excluding ER, OR, Pediatrics and First doses



DOING WHAT'S BEST®

		Beta-lactam Antibiotic Cross-Allergy Chart																
		Pen		1 st Gen	2 nd Gen	3 rd Gen	4 th											
		(cross-reactivity likely; identical R1 or R2 side chain)	(A) = CAUTION	Amoxicillin	Ampicillin	Penicilllin	Piperacillin	Cefazolin	Cephalexin	Cefotaxime	Ceftriaxone	Cefdinir	Ceftazidime	Cefepime	Aztreonam	Ertapenem	Meropenem	Carb
Pen																		
1 st Gen																		
2 nd Gen																		
3 rd Gen																		
4 th																		
Mono																		
Carb																		
Aztreonam																		
Ertapenem																		
Meropenem																		

- Antibiotics Utilizing Extended Infusion Dosing:**
 - Aztreonam (3 hour infusion)
 - Cefepime (4 hour infusion)
 - Ceftazidime (4 hour infusion)
 - Meropenem (3 hour infusion)
 - Piperacillin/Tazobactam (4 hour infusion)

Prescribing Considerations:

- Aztreonam reserved for patient with severe B-lactam allergy (alternative: Cefepime)
- Nitrofurantoin for uncomplicated UTI only

Fluoroquinolone use should be avoided in the following:

- Patients with increased risk of aortic aneurysm, rupture or dissection
- Patients with history of tendonitis or tendon ruptures
- Elderly patients due to increased side effects and hepatotoxicity
- Certain uncomplicated infections (i.e. UTI due to increased E. Coli Resistance)